There is evidence to support that BRAF inhibitors, used alone in NSCLC with BRAF-V600E positive mutation, demonstrate only a modest benefit with no complete responses, 40% partial response, and 30% with disease progression while on treatment [11]. Here, BRAF is linked to non-small cell lung carcinoma.